Jubilant Pharmova Share Price Today

Jubilant Pharmova board approves ₹800 crore NCD issuance via private placement

Jubilant Pharmova board approved issuance of up to ₹800 crore in NCDs via private placement. The issue comprises up to 80,000 debentures of face value ₹1,00,000 each, listed on BSE. Board also sought shareholder approval for a broader ₹2,500 crore debt securities limit. NCDs have a maximum tenure of five years with coupon rates to be determined via bidding.

Jubilant Pharmova shares worth ₹18.28 crore flagged in large trade

Approximately 200,560 shares of Jubilant Pharmova were flagged in a large-trade signal on the NSE. The shares changed hands at ₹911.60 per share, aggregating to ₹18.28 crore. The signal reflects a cluster of trades flagged by a real-time scanning system for size and speed. This is not a confirmed exchange-reported event; official disclosures are published by NSE/BSE only after market close.

Jubilant Pharmova receives ₹87.31 crore GST show cause notice from Mysore

Jubilant Pharmova received a ₹87.31 crore GST show cause notice from Mysore authorities. The demand covers FY23 and includes ₹33.58 crore in tax, interest, and penalty. Allegations involve ineligible ITC and discrepancies in e-waybill records. Company contests the notice as legally incorrect and expects no financial impact.

Jubilant Pharmova faces ₹105.5 Cr GST demand over IGST refund claim

Jubilant Pharmova received a CGST show cause notice proposing a total demand of ₹105.5 crore. The demand includes ₹52.75 crore in tax and an equal penalty for ineligible IGST refunds. The notice targets subsidiary Jubilant Generics for violations in FY21-22. Company disputes the notice as factually incorrect and plans to contest it.

Jubilant Pharmova passes all AGM resolutions, approves ₹5 dividend

Shareholders approved all resolutions at the 48th AGM, including a ₹5 per share dividend. FY26 consolidated revenue grew 14% to ₹83 billion; EBITDA rose 8% to ₹13 billion. Q1FY27 revenue increased 17% to ₹22 billion, though margins faced temporary headwinds. CDMO Sterile Injectables revenue surged 38%, driven by Line 3 launch at Spokane. Directors Hari Shanker Bhartia and Arjun Shanker Bhartia were reappointed by rotation.

Jubilant Pharmova secures USFDA approval for Spokane Line 3 manufacturing

USFDA approved commercial batch manufacturing on Line 3 at Spokane facility. Approval received on August 21, 2026, for first product on isolator-based line. Line specializes in sterile injectables and ophthalmic formulations. Subsidiary Jubilant HollisterStier operates under Jubilant Pharma Holding Inc.